Navigation Links
PinnacleHealth Announces New Investigational Treatment Option For Aortic Stenosis Patients With A Larger Valve Size
Date:6/15/2016

HARRISBURG, Pa., June 15, 2016 /PRNewswire/ -- Today PinnacleHealth enrolled the first patient nationally in a new clinical trial investigating a larger size of the Medtronic CoreValve® Evolut® R System—the Evolut R 34mm System. The larger transcatheter aortic valve replacement (TAVR) technology is designed to treat severe aortic stenosis patients with a larger base of the aortic root, called the annulus, specifically those with an annulus diameter between 26-30mm. Annulus sizes vary between individuals.

For many years, the gold standard treatment for severe aortic stenosis has been open surgery. Surgical aortic valve replacement (SAVR) allows the surgeon to clearly visualize and measure the annulus. With TAVR, physicians rely on advanced imaging technology to model the anatomy of the heart, measure the annulus and select the appropriate valve size. With both SAVR and TAVR, accurate sizing is one factor in long-term patient outcomes. TAVR procedures have been limited to patients with a smaller annulus, specifically a diameter less than 26 mm.

L to R: --- Kenny Thomas, Field Clinical Lead; Jill Pippel, Training and Education; Hatem Tadros, Engineering Manager; Courtney Rodgers, Research Nurse; Regina Hollister, Research Coordinator; Dr. Mubashir Mumtaz; Dr. Hemal Gada; Dr. William Bachinsky; Mark Moquin, Surgical PA-C; Alaena Maiorano, Engineering Manager
L to R: --- Kenny Thomas, Field Clinical Lead; Jill Pippel, Training and Education; Hatem Tadros, Engineering Manager; Courtney Rodgers, Research Nurse; Regina Hollister, Research Coordinator; Dr. Mubashir Mumtaz; Dr. Hemal Gada; Dr. William Bachinsky; Mark Moquin, Surgical PA-C; Alaena Maiorano, Engineering Manager

The CoreValve Evolut R 34mm Valve replaces a diseased aortic heart valve through a minimally invasive procedure, without open-heart surgery and without surgical removal of the diseased valve. The device is typically inserted via an artery in the leg and then guided through the arteries into the heart. Once in place, the device expands and takes over the original valve's function to enable oxygen-rich blood to flow efficiently out of the heart.

Aortic stenosis is a common heart problem caused by a narrowing of the heart's aortic valve due to excessive calcium deposited on the valve leaflets.

When the valve narrows, it does not open or close properly, making the heart work harder to pump blood throughout the body. Eventually, this causes the heart to weaken and function poorly, which may lead to heart failure and increased risk for sudden cardiac death.

The new trial for the Evolut R 34mm System at PinnacleHealth is led by Mubashir Mumtaz, MD, FACS, FACC, chief of cardiothoracic surgery and surgical director of structural heart, and Hemal Gada, MD, MBA, medical director of structural heart.

"Participating in this trial allows us to offer TAVR to a subset of patients who formerly had limited treatment options," says Dr. Mumtaz. "PinnacleHealth continues to be on the forefront of new therapies for patients with aortic stenosis," says Dr. Gada.

The Medtronic Evolut® 34R U.S. Clinical Study is a prospective, single-arm study that will include 60 patients at up to 15 clinical sites. The study is designed to confirm the safety and efficacy of the CoreValve Evolut R 34mm System and to compare the results to the Evolut R IDE. The prospective study will have a primary safety endpoint of all-cause mortality or disabling stroke at 30 days and primary efficacy endpoints of device success and total regurgitation at 30 days.   

The Medtronic Evolut R 34mm System builds off of the CoreValve® Evolut® R transcatheter valve, which was FDA-approved for commercial use in the United States in June 2015 for severe aortic stenosis patients who are at high or extreme risk for surgery.

About PinnacleHealth System
PinnacleHealth System has been a leading provider of inpatient and outpatient healthcare services in central Pennsylvania since 1873. The 636-bed system has three acute care hospitals (Community General Osteopathic, Harrisburg and West Shore Hospitals) on four campuses (Community, Harrisburg, Polyclinic and West Shore) serving a five-county service area and supporting rural hospitals through affiliations and telehealth services. PinnacleHealth pursues innovative treatment options for the region through cardiac and cancer clinical trials, while offering convenient community services including medical home-certified primary care, urgent care, Magnet-recognized nursing excellence, emergency services, imaging, high-volume maternity care and a level III NICU, and workplace-based wellness services. PinnacleHealth includes a CardioVascular Institute and Cancer Institute, as well as a Bone and Joint Institute, Neurosurgery and Neurosciences Institute, and Spine Care Center that combine a multi-disciplinary approach to comprehensive spine, bone, joint, orthopedic and sports medicine services. PinnacleHealth is recognized for high-quality care with national and regional recognitions for volumes, outcomes and safety. For more information, visit pinnaclehealth.org.

CONTACT: Kelly McCall, 717-231-8104, kmccall@PinnacleHealth.org

Photo - http://photos.prnewswire.com/prnh/20160614/378951

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pinnaclehealth-announces-new-investigational-treatment-option-for-aortic-stenosis-patients-with-a-larger-valve-size-300284369.html


'/>"/>
SOURCE PinnacleHealth System
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. PinnacleHealth, Meridian Health Select Perioperative IT from Surgical Information Systems
2. Milner Therapeutics Institute Announces New Partnership With Japanese Pharmaceutical Company Shionogi
3. ViiV Healthcare Announces FDA Approval to Lower the Weight Limit for dolutegravir in Children and Adolescents Living With HIV
4. Global Blood Therapeutics Announces New Clinical Data that Continue to Support Safety and Efficacy Profile of GBT440 as a Potentially Disease-Modifying Therapy for Sickle Cell Disease
5. TapImmune Announces Finalization of License Agreement With Mayo Clinic to Commercialize a HER2neu Vaccine
6. LetterOne Launches L1 Health in US and Announces Franz Humer Appointed to L1 Health Advisory Board
7. Amarantus Completes Sale of Diagnostics Division, Announces Fiscal Year 2015 and First Quarter 2016 Financial Results
8. Maxwell Biotech Venture Funds Portfolio Company Hepatera Announces Publication of Myrcludex B Clinical Results in Journal of Hepatology
9. Mundipharma EDO GmbH Announces First-in-human Clinical Trial of its Lead Compound, EDO-S101
10. Kitov Announces Completion of Manufacturing Pivotal Batches of KIT-302 Required for Registration in the U.S.
11. Amarantus Announces Upcoming Investor Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... ... July 17, 2019 , ... Gwinnett Family Dental Care , located ... of complete dental care, including general and preventative care as well as restorative and ... team of extensively trained dentists, Dr. Kell Gallaher, Dr. Jon Klevansky, Dr. Jason Klevansky, ...
(Date:7/17/2019)... ... July 17, 2019 , ... Cognition Corporation , ... a new e-book on developing user needs for life science products. ... a small part of the compliance process and the guiding force for product ...
(Date:7/17/2019)... ... 16, 2019 , ... Steven C. Bilt, Chief Executive Officer of Smile Brands ... the dental industry during a panel discussion at Dykema’s 6th Annual Definitive Conference for ... Dallas Hotel in Dallas, Texas. , Bilt co-founded Smile Brands Inc. in 1998 and ...
Breaking Medicine Technology:
(Date:7/17/2019)... ... July 17, 2019 , ... Becker's Healthcare is ... hospitals. , The men and women included on this list lead organizations regularly ... EHR implementations as well as the construction of satellite clinics and strategic partnerships ...
(Date:7/17/2019)... ... 17, 2019 , ... Athena Software , a leading ... worldwide, has been awarded a California Multiple Award Schedules (CMAS) agreement by the ... and local government agencies in California by designating pre-approved suppliers from whom they ...
(Date:7/17/2019)... ... July 17, 2019 , ... A new study led ... of the American Medical Association (JAMA), shows for the first time that New ... the state. Sepsis is the body’s extreme response to infection. It kills more than ...
(Date:7/17/2019)... ... 2019 , ... Women’s Excellence is pleased to announce a new office opening in Lapeer, Michigan. ... offices resides on the corner of Turrill Road and South Lapeer Roads, conveniently off of ... opening of our new office in Lapeer and the ability to service women in this ...
(Date:7/13/2019)... ... , ... ZALO , the leading luxury sex toy manufacturer, is now ... To view the product and its accompanying video click here . , “We ... people around the world,” said Mara Epstein, director of sales. “The Hero provides a ...
Breaking Medicine News(10 mins):